-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor Recently, Hirotsu Bio Science announced the successful launch of an innovative pancreatic cancer early screening product, according to the company's press release, this is the world's first test kit
that uses nematodes for early pancreatic cancer screening.
The launch of this product will contribute to the early diagnosis of as many pancreatic cancer cases as possible, contributing to
the improvement of pancreatic cancer treatment outcomes.
▲N-NOSE plus Pancreas' product diagram (Image source: Reference [1])
Traditional cancer detection methods are often powerless for early cancer, and nematodes' perception of cancer just makes up for this defect
。 In a basic study, researchers compared the sensitivity of N-NOSE to various stages of cancer with current detection methods, and they found that N-Nose consistently maintained a high sensitivity to stage 0 and stage 1 cancers in the study, compared to the sensitivity of other tests
.
However, it is worth noting that the N-NOSE test is a cancer screening method, and its test results do not represent a cancer diagnosis
.
According to the product introduction on Hirotsu's official website, N-NOSE testing is actually a cancer risk assessment based on clinical research, the purpose of which is to assess the cancer risk
of subjects.
When the test result is 'no cancer risk detected', it does not prove that the participant does not have cancer, and the test result 'high cancer risk' does not necessarily indicate the presence of cancer
.
Patients should consult their doctor about how to interpret the N-NOSE test results and whether further testing
is needed based on their health.
that uses nematodes for early pancreatic cancer screening.
The launch of this product will contribute to the early diagnosis of as many pancreatic cancer cases as possible, contributing to
the improvement of pancreatic cancer treatment outcomes.
Pancreatic cancer is very difficult to detect in its early stages, and patients are usually diagnosed
at an advanced stage of the disease.
According to the latest cancer statistics, about 30,000 people die from pancreatic cancer each year, and its 5-year survival rate is significantly lower than that of other cancer types
.
Since there is currently no effective pancreatic cancer screening method similar to gastric cancer and colorectal cancer screening, if a method can be developed to detect early pancreatic cancer, the diagnosis and treatment of pancreatic cancer will be a revolutionary progress
.
Hirotsu seeks to develop a highly sensitive test that can diagnose cancer risk with just a drop of urine, regardless of cancer type
.
In this case, the N-NOUS series of detection products has been successfully developed, according to the company's official website product introduction, this test method is expected to screen for 15 types of cancer, including stomach cancer, lung cancer, breast cancer and other common cancer types
.
The N-NOSE test uses the keen olfactory function of nematodes for cancer screening, which is a model organism often used in scientific research, and its sense of smell is very sensitive and highly sensitive to cancer odor in human urine, which is suitable for early diagnosis
of cancer.
In addition, nematodes are inexpensive to propagate and easy to breed, helping to reduce the economic cost of
detection.
In the natural world, nematodes generally live in the soil, because it has no eyes or ears, mainly relies on smell to perceive the environment and search for food, so nematodes have a developed sense of smell and about 1200 olfactory receptor genes, compared to only about 800 olfactory receptors
in dogs known for their sensitive sense of smell.
Because the test takes advantage of the organism's natural abilities, the test is not invasive and therefore does not cause distress to the patient
.
Clinical studies have shown that nematodes respond even to early-stage cancers (stage 0 and I), which are difficult to detect with traditional screening methods
.
Another advantage of N-NOSE over other tests is that it is expected to assess cancer risk in a single test, regardless of where cancer occurs in any part of the body
.
▲N-NOSE plus Pancreas' product diagram (Image source: Reference [1])
Traditional cancer detection methods are often powerless for early cancer, and nematodes' perception of cancer just makes up for this defect
。 In a basic study, researchers compared the sensitivity of N-NOSE to various stages of cancer with current detection methods, and they found that N-Nose consistently maintained a high sensitivity to stage 0 and stage 1 cancers in the study, compared to the sensitivity of other tests
.
However, it is worth noting that the N-NOSE test is a cancer screening method, and its test results do not represent a cancer diagnosis
.
According to the product introduction on Hirotsu's official website, N-NOSE testing is actually a cancer risk assessment based on clinical research, the purpose of which is to assess the cancer risk
of subjects.
When the test result is 'no cancer risk detected', it does not prove that the participant does not have cancer, and the test result 'high cancer risk' does not necessarily indicate the presence of cancer
.
Patients should consult their doctor about how to interpret the N-NOSE test results and whether further testing
is needed based on their health.
Hirotsu said in a press release: "N-NOSE plus Pancreas is expected to make a significant contribution
to the early detection and early treatment of pancreatic cancer.
We are committed to using this technology, which is a fusion of biotechnology and the idea of harnessing the superior capabilities of living organisms themselves, to help save as many lives
as possible.
”
WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering chemical drug development and manufacturing, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and manufacturing
.
If you have relevant business needs, please click the picture below to fill in the specific information
.
